Breast Cancer Research Foundation Launches $100M Venture Fund

The Breast Cancer Research Foundation is committing $100 million to a new venture philanthropy fund that will invest in startups advancing breast cancer research — and recycle any investment returns into new deals, Fortune first reported on September 22, 2026.

The fund launches with $23 million already secured. Philanthropist Karen Hale, BCRF's board chair, and her husband Rob Hale contributed $11 million. Another $12 million comes from a surprise bequest by a donor with no prior relationship to the organization; BCRF has not named that donor, and the bequest will not go entirely to this fund.

BCRF will raise the remaining $77 million over five years to reach its $100 million target. It aims to build a portfolio of 20 to 30 companies across diagnostics, targeted therapies, immuno-oncology, and other emerging technologies.

For the organization founded by Evelyn Lauder more than 30 years ago, the fund marks a shift toward the private sector after decades of grant-making. BCRF president and CEO Donna McKay announced the initiative at the Clinton Global Initiative on September 22.

McKay said the venture philanthropy structure itself is a draw for donors. "There are probably donors who would be as excited or more to fund this than traditional philanthropy," she told Fortune. "It's appealing [to them] that this fund could be evergreen and could be able to continue funding new initiatives over and over again."

An investment committee staffed with experts from both business and science will decide which checks to write. The committee's first bet is Clarity Inc., whose platform Clarity Breast uses AI to analyze mammograms — detecting cancer and predicting a patient's five-year risk of developing the disease.

McKay frames the fund's mandate as filling the "valley of death" in commercial biopharma. Most funding in the sector flows to later-stage companies, while early-stage firms are seeing their share of financing shrink. Women's health, she noted, has always been underfunded.

The goal, McKay explained, is "to be able to step in and fund the next area in between basic science but before capital venture capital funds are likely to put resources in because these investments might be too early or they might be too risky."

BCRF expects to begin writing additional checks in early 2027. Founders interested in the fund can expect more information at that point.

For Hale, the commitment is personal as well as financial. "The money all goes to research," she said of her support for BCRF. "And now it's going to go one step further."

If the portfolio performs, the evergreen structure means BCRF's first $100 million could keep compounding into new breast cancer investments for years — a model that other disease-focused nonprofits may soon be pressed to copy.